Year: 2023
Type: article
Abstract: M.K. has received funding as an advisor/consultant from the following sources: AbbVie, Ionis Pharmaceuticals, Protagonist Therapeutics, Incyte, and MorphoSys. R.H. received research grant funding through his institution from the following sources: Citi BioPharma Corp, Curis, Inc., Dexcel Pharma Technologies Ltd. Genentech, Kartos Therapeutics, Karyopharm Therapeutics, Inc., Kymera Therapeutics, OncoMyx Therapeutics, Novartis, Protagonist Therapeutics, Repare Therapeutics, Translational Drug Development (TD2), Turning Point Therapeutics, and the NIH/NCI. Additionally, he has received funding as an advisor/consultant from the following sources: AbbVie, Ionis Pharmaceuticals, Protagonist Therapeutics, Silence Therapeutics, GlycoMimetics, Dexcel Pharma Technologies LTD, Sumitomo Pharma Oncology, and Cellenkos, Inc. Finally, he holds a share of a patent filed by Dompé farmaceutici S.p.A.; Y.Z.G. received research grant funding through his institution from the following sources: Protagonist Therapeutics, Repare Therapeutics, and the NIH/NIDDK. Additionally, she has received funding as an advisor/consultant from the following sources: Takeda, Denali, Bay Clinical, Ionis Pharmaceuticals, and Protagonist Therapeutics. The remaining authors have no conflicts to report. Data sharing is not applicable to this article as no new data were created or analyzed in this study.
Source: American Journal of Hematology
DOI: 10.1002/ajh.27047
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4385477118